核苷（酸）类药物治疗慢性乙型肝炎患者影响HBeAg血清转换的免疫学因素研究进展*

doi:10.3969/j.issn.1672-5069.2017.03.035

摘要/Abstract

摘要： 宿主的免疫系统功能决定了乙型肝炎病毒(HBV)感染的最终转归。核苷（酸）类药物抗病毒治疗能快速降低病毒载量,恢复宿主的免疫功能,HBeAg血清转换就是宿主免疫系统功能部分恢复的标志。本文介绍了近五年这个领域的相关基础及临床研究,探讨了天然免疫和获得性免疫与HBeAg血清转换的相关性,为提高核苷（酸）类药物抗病毒治疗过程中的HBeAg血清转换率提供依据。

关键词: 慢性乙型肝炎, HBeAg血清转换, 先天性免疫, 获得性免疫, 细胞因子

曹辉, 张玮. 核苷（酸）类药物治疗慢性乙型肝炎患者影响HBeAg血清转换的免疫学因素研究进展^*[J]. 实用肝脏病杂志, 2017, 20(3): 372-376.

Cao Hui, Zhang Wei. Research Progress of Immunological factors influencing HBeAg seroconversion across chronic hepatitis B patients treated with nucleos(t)ide analogues[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 372-376.

参考文献

[1] Stanaway JD,Flaxman AD,Naghavi M,et al.The global burden of viral hepatitis from 1990 to 2013:findings from the Global Burden of Disease Study 2013. Lancet,2016,388(10):1081-1088.
[2] Liu J,Zhang S,Wang Q,et al.Seroepidemiology of hepatitis B virus infection in 2 million men aged 21 49 years in rural China:a population-based,cross-sectional study. Lancet Infect Dis,2015,16(1):80-86.
[3] Sui M,Wu R,Hu X,et al.Lowprevalence of hepatitis B virus infection in patients withautoimmune diseases in a Chinese patient population. J Viral Hepat,2014,21(12):925-929.
[4] Zhang E,Kosinska A,Lu M,et al.Current status of immunomodulatory therapy in chronic hepatitis B,fifty years after discovery of the virus:Search for the “magic bullet” to kill cccDNA. Antivir Res,2015,123(11):193-203.
[5] Sun J,Ma H,Xie Q,et al.Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B:A randomized controlled study. J Hepatol,2016,65(4):674-682.
[6] Gao B,Jeong WI,Tian Z.Liver:An organ with predominant innate immunity.Hepatology,2008,47(2):729-736.
[7] Yang Y,Han Q,Zhang C,et al.Hepatitis B virus antigens impair NK cell function. Int Immunopharmacol,2016,38(9):291-297.
[8] Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology,2011,53(1):73-85.
[9] Boni C,Lampertico P,Talamona L,et al.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B. Hepatology,2015,62(6):1697-709.
[10] Bruder Costa J,Leroy V,Bouvier-Alias M,et al.Pegylated interferon α-2a triggers NK-cell functionality and specific T-Cell responses in patients with chronic HBV infection without HBsAg seroconversion. PLoS One,2016,11(6):1-20.
[11] Marcellin P,Ahn S H,Ma X,et al.Combination of tenofovir disoproxil fumarate and peginterferon INF-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144.
[12] Stelma F,De N A,Tempelmans Plat-Sinnige MJ,et al. NK cell characteristics in chronic hepatitis B patients are associated with HBsAg loss after combination treatment with Peg-interferon alpha-2a and adefovir. J Infect Dis,2015,212(7):1042-1051.
[13] Kumar V.NKT-cell subsets:Promoters and protectors in inflammatory liver disease. J Hepatol,2013,59(3):618-620.
[14] Jiang X,Zhang M,Lai Q,et al.Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B. Plos One,2011,6(12):69-75.
[15] Scroggins SM,Olivier AK,Meyerholz DK,et al.Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. Plos One,2013,8(9):274-283.
[16] Lin C,Zou H,Wang S.Hepatitis B e Antigen seroconversion is related with the function of dendritic cells in chronic Hepatitis B virus infection.Gastroenterol Res Pract,2014,20(14):413-418.
[17] Wei MJ,Pan XN,Wei KP,et al.Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. Int Immunopharmacol,2015,27(2):238-243.
[18] Boltjes A,Groothuismink ZM,van Oord GW,et al. Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. Plos One,2014,9(5):1-9.
[19] Dastjerdi MN,Momeni M,Bidaki R,et al.The effect of depression and anxiety on expression levels of toll like receptor signaling molecules in chronic HBV infected patients. Med J Islam Repub Iran,2015,29(5):841-849.
[20] Durantel D,Zoulim F,Durantel D,et al.Interplay between hepatitis B virus and TLR2-mediated innate immune responses:Can restoration of TLR2 functions be a new therapeutic option [J] Hepatol,2012,57(3):486-489.
[21] Wang S,Chen Z,Hu C,et al.Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation.J Immunol,2013,190(10):5142-5151.
[22] Huang Z,Ge J,Pang J,et al.Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy. Antiviral Res,2015,118(6):10-19.
[23] Yan W,Wu D,Wang X,et al.Upregulation of NKG2C(+) natural killer cells,TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB. Antivir Ther,2015,20(6):591-602.
[24] Zoulim F,Luangsay S,Durantel D.Targeting innate immunity:A new step in the development of combination therapy for chronic hepatitis B. Gastroenterology,2013,144(7):1342-1344.
[25] Lanford R E,Guerra B,Chavez D,et al.GS-9620, an Oral agonist of toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144(7):1508-1517.
[26] Chung RT,Roberts LR,Bisceglie A,et al.HBV-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology,2015,150(3):684-695.
[27] Piao RL,Liu YY,Tian D,et al.Adefovir dipivoxil modulates cytokine expression in Th1/Th2 cells in,patients with chronic hepatitis B. Mol Med Rep,2012,5(1):184-189.
[28] Sprinzl M F,Russo C,Kittner J,et al.Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment. J Viral Hepat,2014,21(9):633-641.
[29] Tian ZF,You ZL,Yi H,et al.Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis B. Ann Hepatol,2016,15(2):174-182.
[30] You J,Yan YZ,Sriplung H,et al.Decline of hepatitis B virus load correlate with increase of Th1/Th2 immunity in chronic hepatitis B patients during long-term treatment with entecavir.Int J Infect Dis,2014,21(4):320.
[31] Staron M,Gray S,Marshall H,et al.The transcription factor foxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+,T Cells during chronic infection. Immunity,2014,41(5):802-814.
[32] Rong F,Jian S,Quan Y,et al.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut,2016,65(2):313-320.
[33] Tang Y,Chen X,Zhang Y,et al.Fusion protein of tapasin and hepatitis B core antigen 18 27 enhances T helper cell type 1/2 cytokine ratio and antiviral immunity by inhibiting suppressors of cytokine signaling family members 1/3 in hepatitis B virus transgenic mice. Mol Med Rep,2014,9(4):1171-1178.
[34] Wang GQ,Ding YP,Dong YH.Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat,2013,20(4):9-17.
[35] Chokshi S,Cooksley H,Riva A,et al.Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.Viral Immunol,2014,27(5):235-244.
[36] Manigold T,Racanelli V.T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections:facts and controversies. Lancet Infect Dis,2008,7(12):804-813.
[37] Shen C,Yan WZ,Zhao CY,et al.Increased CD4+CD25+,regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients. J Microbiol Immunol Infect,2015,48(2):137-146.
[38] Yang J,Ping Y,Li W,et al.Phenotypes and clinical significance of circulating CD4+CD25+,regulatory T cells (Tregs) in patients with acute-on-chronic liver failure(ACLF). J Transl Med,2012,10(1):284-292.
[39] Liu Y,Cheng LS,Wu SD,et al.IL-10-producing regulatory B cells suppressed effector T but enhanced regulatory T cells in chronic HBV infection. Clin Sci (Lond),2016,30(11):907-919.
[40] Yang J,Sheng G,Xiao D,et al.The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4+CD25+ regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment. Cell Mol Immunol,2016,13(5):678-687.
[41] Pavadm,Dushek O.Mechanisms for T cell receptor triggering.Nat Rev Immunol,2011,11(1):47-55.
[42] Fazilleau N,Mark L,Mcheyzer-Williams LJ,et al.Follicular hel-
per T cells:Lineage and location. Immunity,2009,30(3):324-335.
[43] Li Y,Ma S,Tang L,et al.Circulating CXCR5(+) CD4(+) T cells benefit HBeAg seroconversion through IL-21 in patients with chronic HBV infection. Hepatology,2013,58(4):1277-1286.
[44] Hu T T,Song X F,Lei Y,et al.Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J,2013,11(1):1-9.
[45] Zhang L,Zhang M,Li H,et al.TFH cell-mediated humoral immune response and HBsAg level can predict HBeAg seroconversion in chronic hepatitis B patients receiving peginterferon-IFN2αtherapy.Mol Immunol,2016, 73(5):37-45.
[46] Lei Y,Hu T,Song X,et al.Production of autoantibodies in chronic hepatitis B virus infection is associated with the augmented function of blood CXCR5+CD4+T Cells. PLoS One,2016,11(9):1-9.

核苷（酸）类药物治疗慢性乙型肝炎患者影响HBeAg血清转换的免疫学因素研究进展^*

Research Progress of Immunological factors influencing HBeAg seroconversion across chronic hepatitis B patients treated with nucleos(t)ide analogues

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[11]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[12]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[13]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[14]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[15]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.